Stockreport

Foghorn Therapeutics Announces Significant Progress for Selective ARID1B Degrader at the 8th Annual TPD and Induced Proximity Summit

Foghorn Therapeutics Inc.  (FHTX) 
PDF CAMBRIDGE, Mass., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicin [Read more]